ArticleChemistryEurope2026
ENDONUCLEASE V: FROM TRANSCRIPTOME REGULATOR TO CHEMICAL BIOLOGY TOOL.
Article in ChemistryEurope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Posttranscriptional modifications play a pivotal role in regulating the health and physiology of human cells and adenosine-to-inosine (A-to-I) editing is one of the most abundant of these modifications. Inosine is read as guanosine by the cellular machinery and this change impacts both the regulation and genetic code of RNA, in turn effectively rewiring both the transcriptome and proteome. Given these crucial functions, it is not surprising that A-to-I editing is implicated in a number of disease processes, including cancers and neurological disorders. While ADARs have been identified as the primary writers for inosine modification, putative readers and erasers have received far less attention. Recent studies have revealed that the Endonuclease V (EndoV) family of enzymes has the unique ability to detect and cleave inosine-containing RNAs, suggesting that EndoV may regulate the fate of edited RNAs in the cell. Despite this potentially important role, human Endonuclease V (hEndoV) remains relatively understudied, and in some cases, conflicting results have been presented regarding the activity of hEndoV. Here, we aim to bring together this existing knowledge in order to further spur investigation into this potentially crucial regulator of A-to-I editing. We first describe biochemical and structural studies that reveal the molecular aspects of inosine recognition and RNA cleavage, and the evolution of these functions from DNA repair in prokaryotes to RNA cleavage in eukaryotes. Based upon this knowledge, we discuss reports suggesting the role of hEndoV in human physiology. Finally, we highlight technologies that leverage EndoV for mapping and quantifying A-to-I editing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.